Hedera Dx Information

Liquid biopsies provide more therapy options for more patients. With 1 in 3 people likely to be diagnosed with cancer in their lifetime and the rapid evolution of precision oncology over the past decades to deliver more efficient and personalized treatments, cancer requires to be swiftly analyzed on a molecular level and timely matched with the best therapy options, to ultimately improve patients’ outcomes and experiences. NGS-based liquid biopsies represent one of the most transformational innovations in cancer care for the next decade - enabling non-invasive cancer diagnosis, treatment selection and disease monitoring - and they are increasingly entering the clinic. The information gathered from these analyses takes our awareness of cancer to the next level, unlocking new possibilities of diagnosis and cancer care. Co-founded in 2021 by Tommi Lehtonen, Damien Lapray and Christian Meisel with the purpose to give access to liquid biopsy technologies to all cancer patients, Hedera Dx is an ambitious, fast growing and passionate scale-up employing 20+ people across Switzerland and Europe. Our culture is based on thinking different, modern and human: basically, on being ourselves. This goes into everything we do: from how we develop our products to the way we work and who we hire. Beyond the complexity and seriousness of what we aim at solving, we make sure to daily enjoy what we do and to celebrate every success. If you want to have a taste of Hedera Dx, you’re warmly welcome to drop by our offices in Lausanne and Helsinki for a coffee (it’s on us) or to connect with us remotely to e-meet our team.